Consolidated Finvest & Holdings Limited

Financial Services — Capital Markets · NSE

₹293.65+₹3.70 (+1.28%)

DalalBaazaar Score

60 / 100

🟢 Good

Verdict

CAUTION

Risk

Moderate

Driven by negative free cash flow, micro-cap size, which brings thin liquidity.

In simple words: The business is earning a fairly low return on the money invested in it, with modest growth. Cash generation is currently the main factor to watch.

Decision support, not a buy or sell call.

As of 18 Oct 2026, 7:44 pm

Understanding the Business

Company site ↗

The 60-second version of Consolidated Finvest & Holdings Limited — what it does, how it earns, and who it competes with, before any of the numbers below.

What does this company do?

Consolidated Finvest & Holdings Limited, a non-banking financial company, engages in the lending and investment business in India.

IndustryCapital Markets

SectorFinancial Services

Employees2

Annual revenue₹7 Cr

How does it make money?

Turns over ₹7 Cr a year. Of every ₹100 of sales, about ₹792 reaches shareholders as profit, with ₹905 left at the operating level before interest, tax and depreciation. Each of its 2 employees supports ₹3.41 Cr of revenue a year, the signature of a capital- or asset-led business.

Revenue / employee₹3.41 Cr

Who are its competitors?

The closest listed comparisons in its industry are BAJAJ FINANCE LIMITED, HDFC LIFE INS CO LTD, SBI LIFE INSURANCE CO LTD. These are the companies its valuation and returns are measured against elsewhere in this report.

Compared side by side in Peers ↓

What is its competitive advantage?Not assessable from these ratios

For a lender, returns on capital are shaped by leverage and funding cost rather than by pricing power, so the usual financial signature of an advantage does not apply. Judge this one on deposit franchise, cost of funds and asset quality — none of which are in this data.

Peer median ROE13.7%

What has been driving growth?

Growth has come mainly from selling more, rather than from keeping more of each sale. Over 3 years revenue moved +201% while net margin moved -94% relative to itself. What this cannot tell you is which products, customers or geographies did the work — that lives in the segment disclosures of the annual report.

Revenue effect+201%

Margin effect-94%

DalalBaazaar Score

60/ 100

Good

Weighted across six categories. Every point is explained below.

✓ Beta of 0.56 — historically steadier than the index
✗ Micro Cap: thinner liquidity and sharper drawdowns are normal
✗ Profits have swung sharply from year to year — earnings are hard to forecast
✗ Negative free cash flow means dependence on external funding

Quality vs. Valuation

Company Quality

63/ 100

Average

How good the business is, ignoring the share price entirely.

Valuation

49/ 100

Fair

What you are being asked to pay, ignoring how good the business is.

A reasonable business at a reasonable price — neither the quality nor the valuation stands out in either direction.

Historical Valuation

Current P/E

17.6x

3Y Median

6.7x

40 monthly readings · mean 8.4x · range 1.5x–17.7x

Sector Median

58.4x

median of 3 sector peers

⚠️Current valuation is approximately 161% above its 3y median of 6.7x. Paying more than usual needs a reason — faster growth, a better balance sheet, or a re-rating you believe in.

🟢Against its sector it trades 70% below the peer median of 58.4x.

vs. its own history

Expensive

6.7x median over 40 months · +161%

vs. sector peers

Cheap

58.4x median of 3 peers · -70%

vs. generic bands

Fair

15x–35x

EV/EBITDA

15.4x

PEG

6.75

What's Good / What's Bad

🟢 What's Going Well1

Consistently profitable
Profitable in every one of the last 4 reported years.

🔴 What Needs Attention2

Return on equity is falling
ROE has dropped from 42.1% to 4.7% — each rupee of shareholder capital earns less than it did.
Return on capital is falling
ROCE has declined from 47.8% to 4.8% — often a sign of competition or overexpansion.

Red Flags

2 items require attention · 1 high · 1 watch

🔴Significant margin compressionFinancial
EBITDA margin has fallen 16939.7 points, from 17844.3% to 904.6%.
🟡Profit is decliningFinancial
Net profit is down 83% over 3 years.

Investment Thesis

🟢 Bull CaseWhat could make this work?

Cheaper than its peers
It trades 70% below the sector median. Either the market sees a problem the numbers do not show, or the discount closes.
Earnings have proved durable
Profitable in every one of the last 4 reported years. Consistency lowers the risk that any single bad year is structural rather than cyclical.

🔴 Bear CaseWhat could go wrong?

Margins are being competed away
EBITDA margin has fallen from 17844.3% to 904.6%. If the trend continues, profit falls even on flat sales — and margin decline rarely reverses quickly.
The price already assumes success
The stock trades 161% above its own median multiple. At this level the business has to deliver just to stand still, and a stumble is repriced twice — lower earnings on a lower multiple.
Returns on shareholder capital are falling
ROE has dropped from 42.1% to 4.7%. Each rupee of equity earns less than it did, so profit growth increasingly depends on raising more capital rather than on the existing base working harder.
Earnings are hard to forecast
Profit has swung sharply from year to year, so any single year — good or bad — is a weak guide to the next. Cyclical earnings deserve lower multiples for that reason.
Size brings its own risk
Micro Cap businesses are thinly traded, so exits are harder in a falling market and single events move the price more than they would for a larger company.

🟡 Key Things to WatchMeasurable tripwires, set against where this company stands today

1Revenue growth stays above 33% a year✓ 44.4% CAGR
Latest reported year was 2.5%. The bar is set below the established compounding rate, so ordinary variation does not trip it.
2EBITDA margin holds above 903%✓ 904.6%
Two points below today's level — enough room for noise, tight enough to catch real compression.
3Return on equity stays above 8%✗ 4.7%
For a lender this is the cleanest single read on whether the book is being grown profitably.
4Valuation vs its own median of 6.7x✗ 17.6x today
A re-rating above its own history needs a reason; without one it is just a higher price.

Investment Checklist

7 / 10 checks passed

✗ Strong return on equity (ROE ≥ 15%)
✗ Strong return on capital employed (ROCE ≥ 15%)
✓ Healthy net margin (≥ 10%)
✗ Generates positive free cash flow
✓ Adequate short-term liquidity (Current Ratio ≥ 1.0)
✓ Revenue growing year-over-year
✓ Profit growing year-over-year
✓ Not trading at an extreme valuation (P/E < 40x)
✓ Not buying right at the 52-week high
✓ Short-term technical trend isn't bearish

Price history

Quick Metrics

2 good · 6 neutral · 3 weak

Market Cap

₹949 Cr

Micro Cap

Smaller company — thin liquidity and deep drawdowns are normal here

P/E (Trailing)

17.6x

Fair

Fairly valued against the generic band

P/B Ratio

0.82x

Reasonable

Reasonable against the company's book value

EPS (TTM)

₹16.73

Profitable

Profitable on a per-share basis

ROE

4.7%

Weak

Weak capital efficiency

ROCE

4.8%

Weak

Low return on total capital employed

Debt/Equity

Not available

No data

Source didn't return this field

Revenue Growth (YoY)

2.5%

Modest

Modest growth

Profit Growth (YoY)

2.6%

Modest

Slow profit growth

Dividend Yield

0.50%

Modest

Small cash return — most of the return has to come from the price

Free Cash Flow

-₹1 Cr

Cash burning

Spending more cash than the operations bring in

More Metrics

Operating Margin

99.0%

Good

Healthy core-business profitability

Net Margin

86.8%

Good

Strong bottom-line conversion

Current Ratio

5163.42

Comfortable

Healthy short-term liquidity

Beta (vs Nifty)

0.56

Defensive

Steadier than the market

52W Range Position

84%

Mid-range

Technical Snapshot

SMA 20 / SMA 50

289.1 / 285.5

Bullish alignment (short > long)

Price vs SMA 200

Above

Long-term uptrend

RSI (14)

58.1

Neutral momentum

Financial Trend (4-Year)

Metric	FY23	FY24	FY25	FY26	3Y CAGR
Revenue	₹2 Cr	₹14 Cr	₹15 Cr	₹7 Cr	+44.4%
EBITDA	₹404 Cr	₹49 Cr	₹69 Cr	₹62 Cr	-46.5%
EBITDA Margin	17844.3%	363.1%	463.2%	904.6%	—
PAT (Net Profit)	₹313 Cr	₹46 Cr	₹108 Cr	₹54 Cr	-44.3%
EPS	₹96.81	₹14.37	₹33.49	₹16.73	-44.3%
ROE	42.1%	5.7%	10.5%	4.7%	—
ROCE	47.8%	5.5%	6.3%	4.8%	—
Free Cash Flow	₹8 Cr	₹14 Cr	₹10 Cr	-₹1 Cr	—

🟢 Revenue has grown at 44.4% a year over 3 years.

🔴 EBITDA has shrunk at 46.5% a year over 3 years.

🔴 EBITDA Margin has fallen from 17844.3% to 904.6% over 3 years (-16939.7 pts).

🔴 PAT (Net Profit) has shrunk at 44.3% a year over 3 years.

🔴 EPS has shrunk at 44.3% a year over 3 years.

🔴 ROE has fallen from 42.1% to 4.7% over 3 years (-37.4 pts).

🔴 ROCE has fallen from 47.8% to 4.8% over 3 years (-43.0 pts).

🔴 Free Cash Flow has turned negative, from ₹8 Cr to -₹1 Cr.

Balance Sheet & Cash Flow — FY2026

Total Assets

₹1,276 Cr

Total Liabilities

₹117 Cr

Total Debt

—

Cash & Equivalents

₹0 Cr

Operating Cash Flow

-₹1 Cr

Capex

—

Corporate Actions

Dividend Rate

₹1.47

Ex-Dividend Date

11 Sept 2026

Peer Comparison

Company	P/E	ROE
BAJAJ FINANCE LIMITED	30.2x	17.8%
HDFC LIFE INS CO LTD	58.4x	11.3%
SBI LIFE INSURANCE CO LTD	63.9x	13.7%

Recent News

2 mixed4 general

Consolidated Finvest & Holdings Ltd. Upper Circuit: Price and Key Data

Univest, 29 Sept

Consolidated Finvest & Holdings (NSE:CONSOFINVT): What Does Its Q2 FY27 Depository Compliance Filing Mean?

Kalkine India, 14 OctResults

🟡Mixed / dependsA results event. The figures on this page update once the new statements reach the data feed, which usually lags the announcement.

Benign Growth For Consolidated Finvest & Holdings Limited (NSE:CONSOFINVT) Underpins Its Share Price

Simply Wall Street, 28 Jan

Consolidated Finvest & Holdings Ltd. Peer Comparison – Compare with Others

Value Research, 12 Sept

Consolidated Finvest & Holdings Q1 FY27 Results Preview

Univest, 08 JulResults

🟡Mixed / dependsA results event. The figures on this page update once the new statements reach the data feed, which usually lags the announcement.

Consolidated Finvest & Holdings Ltd. Key Financial Ratios – Valuation, Profitability & More

Value Research, 01 Sept

Watch Items

This is a financial-sector business: borrowing is its raw material, not leverage in the usual sense. Debt/Equity and ROCE here aren't comparable to a manufacturer's — read them alongside NIM, GNPA and capital adequacy from the company's own disclosures.
Cross-check against the company's latest quarterly filing / investor presentation before acting.
1 metric couldn't be retrieved for this stock — this is more common for smaller or thinly-covered listings.

DalalBaazaar Thesis

StrongBusiness Quality · Financial Health

MiddlingProfitability · Valuation

WeakGrowth · Risk

Points for each in the Score ↑

Unremarkable in both directions

A reasonable business at a reasonable price. Nothing here is alarming and nothing is compelling, which usually means the decision rests on things this data cannot see — the industry's direction, management's intent, and what else is available to you. 1 high-severity red flag sits above this conclusion and should be read first.

2 of 4 tripwires tripped — Return on equity stays above 8%; Valuation vs its own median of 6.7x · see Key things to watch ↑